Turning patient data into proprietary medicine in clicks, not years.
gmRNA™ is Spheroid AI's agentic platform: it turns each patient's tumor profile into optimized, ready-to-manufacture mRNA sequences. Our team combines generative sequence design, in-vitro validation workflows, and manufacturing integration to deliver truly individualized therapies at scale — starting with drug-resistant ovarian cancer.
Julia is the conversational agent inside gmRNA™. Watch her orchestrate agentic mRNA construct design, in-vitro validation planning, and manufacturing handoff — from a single tumor transcriptomic dataset.
| Patient ID | Tumor features | Candidate targets | mRNA construct | Design score | Manufacturability | Validation plan |
|---|---|---|---|---|---|---|
| P-001 | BRCA1-mut, TP53-LOF | KRAS, VEGFR2 | mRNA-4821-v3 | 0.91 | High | Prolif + Casp-3 |
| P-002 | BRCA2-wt, PIK3CA-mut | HER2, mTOR | mRNA-5033-v1 | 0.87 | Medium | Apoptosis + PARP |
Patient RNAseq data
patient_RNAseq.csv
Virtual tumor model
Multi-omics AI
Individualized design
A,A,U,G,C…A,A,U,C,G
Julia
mRNA design assistant
Tumor profile for P-001 ingested. BRCA1 mutation detected with TP53 loss-of-function. I've identified KRAS and VEGFR2 as candidate targets. Ready to generate mRNA construct candidates. Shall I proceed?
Yes — design constructs with GC content constraints and flag any off-target risks.
Generated 3 construct candidates. Top candidate mRNA-4821-v3 has a design score of 0.91, GC content 48.2%, no off-target flags, and high manufacturability. Want to see the validation plan?
Yes, and flag any immunogenicity risks.
Validation plan ready: proliferation assays at 48h and 72h, Caspase-3/7 activation readout, PARP cleavage western blot. No immunogenicity flags; one minor 5′ UTR motif advisory is documented in the design rationale.
From tumor profiling to manufacturing handoff, gmRNA™ orchestrates every step of the mRNA design pipeline — with Julia as your copilot.
Julia — central orchestrator
At the heart of gmRNA™, specialized agents — orchestrated by Julia — profile tumors, design optimized mRNA constructs, plan in-vitro validation assays, and generate ready-to-manufacture packages with full traceability.
Upload omics and pathology summaries; Julia standardizes them into a design-ready tumor profile.
Multi-agent reasoning and generative sequence design with constraints for GC content, motifs, off-target screening, and manufacturability.
Experimental plans for proliferation, apoptosis assays, and protein marker readouts, tailored to each construct.
Export ready-to-manufacture packages — sequence files, specifications, and QC checklists — to your CDMO partners.
Screen for sequence liabilities, off-target effects, and immunogenicity heuristics with documented risk advisories.
Version every construct with complete design rationale — from tumor profile to final sequence.
From bench to manufacturing, gmRNA™ supports the programs that define the next generation of precision oncology.
Rapid iteration on personalized mRNA constructs for resistant phenotypes — compressing the design-to-validation cycle.
Standardize mRNA design and validation workflows across cell lines and patient-derived models with reproducible pipelines.
A clean handoff from design to synthesis and manufacture — with traceable specs, QC checklists, and version-controlled packages.
A small team with deep roots in cancer intelligence, generative biology, and the commercial realities of pharma. We combine decades of research with the agility of software.
Ph.D.
Co-founder & CEO
Spent 10+ years building the “ground truth” dataset for cancer metabolism. Turns biological complexity into a software problem.
Prof., Ph.D.
Scientific Co-founder
Pioneer of complex bio-simulations. Built the engine that lets us run “digital trials” in seconds — before we ever touch a lab.
M.Sc.
Chief Financial Officer
Leads finance and fund management at Spheroid AI. Structures capital and runway so the science can move at software speed.
M.Sc.
Business Development
US-market expert focused on “Pharma-as-a-Customer.” Bridges generative code and global drug manufacturing.
In good company
Everything you need to know about the platform, the science, and how we work with R&D teams across Canada and beyond.
For research use and development purposes only. Not intended as medical advice.
